Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott, Jeffrey A. Sosman, Mario Sznol, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 8, pp. 833-842
Closed Access | Times Cited: 539

Showing 26-50 of 539 citing articles:

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
Peter Makhov, Shreyas Joshi, Pooja Ghatalia, et al.
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 7, pp. 1355-1364
Open Access | Times Cited: 410
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
Solange Peters, Scott Gettinger, Melissa L. Johnson, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 24, pp. 2781-2789
Open Access | Times Cited: 374
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher, Sarah Warren, Rongze Lu, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 361
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Yilun Wu, Weiyu Chen, Zhi Ping Xu, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 354
Combination immunotherapy: a road map
Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, et al.
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 344
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 3, pp. 405-415
Open Access | Times Cited: 332
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M. Taube, Jérôme Galon, Lynette M. Sholl, et al.
Modern Pathology (2017) Vol. 31, Iss. 2, pp. 214-234
Open Access | Times Cited: 325
What does PD-L1 positive or negative mean?
Antoni Ribas, Siwen Hu‐Lieskovan
The Journal of Experimental Medicine (2016) Vol. 213, Iss. 13, pp. 2835-2840
Open Access | Times Cited: 301
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou, Constantinos Alifieris, Dimitrios T. Trafalis
Pharmacology & Therapeutics (2018) Vol. 194, pp. 84-106
Closed Access | Times Cited: 291
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette, Corina Andreescu, Filip Cools, et al.
Hormone and Metabolic Research (2019) Vol. 51, Iss. 03, pp. 145-156
Open Access | Times Cited: 288
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar, Jeffrey S. Weber
Cancer Immunology Immunotherapy (2017) Vol. 66, Iss. 5, pp. 551-564
Open Access | Times Cited: 282
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Varun Sasidharan Nair, Eyad Elkord
Immunology and Cell Biology (2017) Vol. 96, Iss. 1, pp. 21-33
Open Access | Times Cited: 267
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
Andrea Necchi, Richard W. Joseph, Yohann Loriot, et al.
Annals of Oncology (2017) Vol. 28, Iss. 12, pp. 3044-3050
Open Access | Times Cited: 245
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri, James Larkin, Mototsugu Oya, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 4, pp. 451-460
Closed Access | Times Cited: 243
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
V. Sibaud, Nicolás Meyer, Laurence Lamant, et al.
Current Opinion in Oncology (2016) Vol. 28, Iss. 4, pp. 254-263
Closed Access | Times Cited: 240
Prevalence ofPDL1Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman, David Piccioni, Shumei Kato, et al.
JAMA Oncology (2018) Vol. 4, Iss. 9, pp. 1237-1237
Open Access | Times Cited: 226
PD‐1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’
Raul S. González, Safia N. Salaria, Caitlin Bohannon, et al.
Histopathology (2016) Vol. 70, Iss. 4, pp. 558-567
Closed Access | Times Cited: 216
Checkpoint inhibitor immunotherapy in kidney cancer
Wenxin Xu, Michael B. Atkins, David F. McDermott
Nature Reviews Urology (2020) Vol. 17, Iss. 3, pp. 137-150
Closed Access | Times Cited: 216
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Mohamed A. Alfaleh, Hashem O. Alsaab, Ahmad Bakur Mahmoud, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 213
Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
Brant A. Inman, Thomas A. Longo, Sundhar Ramalingam, et al.
Clinical Cancer Research (2016) Vol. 23, Iss. 8, pp. 1886-1890
Open Access | Times Cited: 206
Cutaneous adverse effects of the immune checkpoint inhibitors
Lindsey K. Collins, Michael Chapman, Joi B. Carter, et al.
Current Problems in Cancer (2016) Vol. 41, Iss. 2, pp. 125-128
Closed Access | Times Cited: 205
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 1, pp. 78-86
Open Access | Times Cited: 202
Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
Kiyonori Tanoue, Amanda Rosewell Shaw, Norihiro Watanabe, et al.
Cancer Research (2017) Vol. 77, Iss. 8, pp. 2040-2051
Open Access | Times Cited: 197
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
Daniel Wang, Fei Ye, Shilin Zhao, et al.
OncoImmunology (2017) Vol. 6, Iss. 10, pp. e1344805-e1344805
Open Access | Times Cited: 182
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
Young‐Jun Park, Da‐Sol Kuen, Yeonseok Chung
Experimental & Molecular Medicine (2018) Vol. 50, Iss. 8, pp. 1-13
Open Access | Times Cited: 181

Scroll to top